Global Type 2 Angiotensin II Receptor Market Pipeline Review, H2 2017

“The Report Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor-Pipeline Review, H2 2017, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

View Report @ https://www.marketresearchreports.biz/reports/1361367/type-2-angiotensin-ii-receptor-angiotensin-ii-type-2-receptor-or-agtr2-pipeline-review-h2-2017-market-research-reports

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory, Womens Health, Gastrointestinal and Oncology which include indications Diabetic Nephropathy, Idiopathic Pulmonary Fibrosis, Polycystic Ovarian Syndrome, Acute Ischemic Stroke, Atherosclerosis, Cardiomyopathy, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Dementia Associated With Alzheimers Disease, Dermatitis, Diabetic Neuropathic Pain, Hyperlipidemia, Hypertension, Inflammation, Inflammatory Pain, Kidney Fibrosis, Leiomyosarcoma, Multiple Sclerosis, Myocardial Infarction, Neuromyelitis Optica (Devics Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Postherpetic Neuralgia, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Skin Inflammation, Spinal Cord Injury, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361367

Scope

– The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
– The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
– The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1361367

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Companies Involved in Therapeutics Development
CJ HealthCare Corp
MorphoSys AG
Novartis AG
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Drug Profiles
(amlodipine besylate + valsartan)+ atorvastatin calcium-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMA-401-Drug Profile
Product Description
Mechanism Of Action

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

Comments

comments

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *